Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been given an average rating of “Moderate Buy” by the five brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $5.83.

SRTS has been the subject of several research analyst reports. Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Finally, Lake Street Capital cut their price target on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th.

Insider Activity

In related news, Director Eric Sachetta acquired 37,537 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The shares were bought at an average cost of $3.44 per share, with a total value of $129,127.28. Following the completion of the purchase, the director directly owned 267,480 shares in the company, valued at $920,131.20. The trade was a 16.32% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders have purchased 120,171 shares of company stock worth $405,230. Corporate insiders own 10.20% of the company’s stock.

Hedge Funds Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRTS. Bank of New York Mellon Corp purchased a new position in shares of Sensus Healthcare during the second quarter valued at $303,000. BlackRock Inc. purchased a new position in Sensus Healthcare in the 2nd quarter worth about $252,000. Finally, EP Wealth Advisors LLC acquired a new stake in Sensus Healthcare during the second quarter worth $49,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock opened at $2.86 on Friday. The business has a fifty day simple moving average of $3.01 and a two-hundred day simple moving average of $3.50. The company has a market capitalization of $47.08 million, a price-to-earnings ratio of -3.04 and a beta of 1.18. Sensus Healthcare has a 1 year low of $2.66 and a 1 year high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%. The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $4.60 million.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin.

Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.

Founded in 2010, Sensus Healthcare is headquartered in Boca Raton, Florida.